국소 진행성 두경부암 환자에서의 Docetaxel과 Cisplatin 유도화학요법

• 영문명: Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer
• 발행기관: 대한두경부종양학회
• 저자명: 조은희(Eun Hee Cho) 조근혁(Keun Hyok Cho) 송영봉(Young Bong Song) 최익성(Ik Sung Choi) 최재원(Jae Won Choi) 남승현(Seung Hyun Nam) 김봉석(Bong Seog Kim)
• 간행물 정보: 『대한두경부종양학회지』제21권 제2호, 126~131쪽, 전체 6쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2005.11.30

영문 초록

Objectives: To evaluate the efficacy and safety of induction chemotherapy with docetaxel and cisplatin in locally advanced head and neck cancer. Materials and Methods: Between June 1998 and December 2004, 30 patients were enrolled and among them, 20 patients were evaluable. Patients were treated with docetaxel 75mg/m² and cisplatin 60mg/m² on day 1 every 21 days. Results: The median age was 71(range 54-80) years old. All 20 patients were male. Nineteen patients had pathologically squamous cell carcinoma and 1 had undifferentiated carcinoma. Fourteen of 20 patients(70%) demonstrated an objective response with two(10%) achieving a complete clinical response and eleven(60%) a partial response. The median response duration was 5.3(1.6-32.1) months and the median time to progression was 5.6(1.4-33.8) months. The median overall survival of all patients was 14(range 2.2-34) months. The median overall survival of responders was 17.5(range 5-34) months and that of non-responders was 3.2(range 2.2-23) months, but it was not statistically significant(p=0.106). During a total of 92 cycles, granulocytopenia worse than CTC(Common toxicity criteria) grade 2 occurred in 6%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non-hematologic toxicities were minor and easily controlled. Conclusion: The induction chemotherapy of docetaxel and cisplatin has moderate efficacy with acceptable toxicities in patients with locally advanced head and neck cancer.

목차

Abstract

서론

대상 및 방법

결과

고찰

결론

References

키워드

국소 진행성 두경부암 유도화학요법 Head and neck cancer Docetaxel Cisplatin